These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35112378)

  • 41. Clinical Meaningfulness of Response to Tanezumab in Patients with Chronic Low Back Pain: Analysis From a 56-Week, Randomized, Placebo- and Tramadol-Controlled, Phase 3 Trial.
    Markman JD; Schnitzer TJ; Perrot S; Beydoun SR; Ohtori S; Viktrup L; Yang R; Bramson C; West CR; Verburg KM
    Pain Ther; 2022 Dec; 11(4):1267-1285. PubMed ID: 35962939
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tanezumab Reduces Pain in Women with Interstitial Cystitis/Bladder Pain Syndrome and Patients with Nonurological Associated Somatic Syndromes.
    Nickel JC; Mills IW; Crook TJ; Jorga A; Smith MD; Atkinson G; Krieger JN
    J Urol; 2016 Apr; 195(4 Pt 1):942-8. PubMed ID: 26576710
    [TBL] [Abstract][Full Text] [Related]  

  • 43. First-in-human randomized clinical trials of the safety and efficacy of tanezumab for treatment of chronic knee osteoarthritis pain or acute bunionectomy pain.
    Walicke PA; Hefti F; Bales R; Lu SP; Ruckle JL; Brown MT; West CR; Shelton DL
    Pain Rep; 2018 May; 3(3):e653. PubMed ID: 29922745
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain.
    Schnitzer TJ; Ekman EF; Spierings EL; Greenberg HS; Smith MD; Brown MT; West CR; Verburg KM
    Ann Rheum Dis; 2015 Jun; 74(6):1202-11. PubMed ID: 24625625
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritis.
    Conaghan PG; Abraham L; Viktrup L; Cislo P
    BMC Musculoskelet Disord; 2022 Feb; 23(1):106. PubMed ID: 35105318
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti-nerve growth factor antibodies for the treatment of low back pain.
    Patel F; Hess DK; Maher DP
    Expert Rev Clin Pharmacol; 2020 Jun; 13(6):631-639. PubMed ID: 32436473
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Design of a randomized, placebo-controlled, phase 2 study evaluating the safety and efficacy of tanezumab for treatment of schwannomatosis-related pain.
    Da JLW; Merker VL; Jordan JT; Ly KI; Muzikansky A; Parsons M; Wolters PL; Xu L; Styren S; Brown MT; Plotkin SR
    Contemp Clin Trials; 2022 Oct; 121():106900. PubMed ID: 36038003
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tanezumab: Therapy targeting nerve growth factor in pain pathogenesis.
    Patel MK; Kaye AD; Urman RD
    J Anaesthesiol Clin Pharmacol; 2018; 34(1):111-116. PubMed ID: 29643634
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model.
    LaBranche TP; Bendele AM; Omura BC; Gropp KE; Hurst SI; Bagi CM; Cummings TR; Grantham LE; Shelton DL; Zorbas MA
    Ann Rheum Dis; 2017 Jan; 76(1):295-302. PubMed ID: 27381034
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and Safety of Tanezumab on Osteoarthritis Knee and Hip Pains: A Meta-Analysis of Randomized Controlled Trials.
    Chen J; Li J; Li R; Wang H; Yang J; Xu J; Zha Z
    Pain Med; 2017 Feb; 18(2):374-385. PubMed ID: 28034979
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial.
    Brown MT; Murphy FT; Radin DM; Davignon I; Smith MD; West CR
    J Pain; 2012 Aug; 13(8):790-8. PubMed ID: 22784777
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials.
    Xiang H; Liu L; Gao Y; Ahene A; Collins H
    Cancer Chemother Pharmacol; 2021 Nov; 88(5):899-910. PubMed ID: 34383128
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neurological safety of subcutaneous tanezumab versus NSAID in patients with osteoarthritis.
    Brown MT; Sandroni P; Low PA; Gorson KC; Hunter DJ; Pixton GC; Fountaine RJ; Viktrup L; West CR; Verburg KM
    J Neurol Sci; 2022 Mar; 434():120184. PubMed ID: 35217440
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of tanezumab in the treatment of pain from bone metastases.
    Sopata M; Katz N; Carey W; Smith MD; Keller D; Verburg KM; West CR; Wolfram G; Brown MT
    Pain; 2015 Sep; 156(9):1703-1713. PubMed ID: 25919474
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrations.
    Bihorel S; Fiedler-Kelly J; Ludwig E; Sloan-Lancaster J; Raddad E
    AAPS J; 2014 Sep; 16(5):1009-17. PubMed ID: 24912797
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain.
    Bramson C; Herrmann DN; Carey W; Keller D; Brown MT; West CR; Verburg KM; Dyck PJ
    Pain Med; 2015 Jun; 16(6):1163-76. PubMed ID: 25594611
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Population Pharmacokinetics (PK) and Pharmacodynamics (PD) Analysis of LY3015014, a Monoclonal Antibody to Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Healthy Subjects and Hypercholesterolemia Patients.
    Shen T; James DE; Krueger KA
    Pharm Res; 2017 Jan; 34(1):185-192. PubMed ID: 27822850
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy, Safety, and Tolerability of Fulranumab as an Adjunctive Therapy in Patients With Inadequately Controlled, Moderate-to-Severe Chronic Low Back Pain: A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Dose-loading Phase II Study.
    Sanga P; Polverejan E; Wang S; Kelly KM; Thipphawong J
    Clin Ther; 2016 Jun; 38(6):1435-1450. PubMed ID: 27101815
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Population pharmacokinetics and probability of target attainment of ertapenem administered by subcutaneous or intravenous route in patients with bone and joint infection.
    Goutelle S; Valour F; Gagnieu MC; Laurent F; Chidiac C; Ferry T;
    J Antimicrob Chemother; 2018 Apr; 73(4):987-994. PubMed ID: 29244077
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain.
    Cattaneo A
    Curr Opin Mol Ther; 2010 Feb; 12(1):94-106. PubMed ID: 20140821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.